Quviviq vs Belsomra
A side-by-side look at two sleep medications advertised on TV. Informational only — not medical advice.
| US Quviviq | US Belsomra | |
|---|---|---|
| Generic name | daridorexant | suvorexant |
| Drug class | Dual Orexin Receptor Antagonist | Orexin Receptor Antagonist |
| Treats | Insomnia | Insomnia |
| Category | Sleep | Sleep |
| Manufacturer | Idorsia | Merck |
| Year approved | 2022 | 2014 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $75M | — |
| Common side effects | Headache, Next-day drowsiness, Dizziness, Nausea | Next-day drowsiness, Headache, Dizziness, Abnormal dreams |
Frequently asked questions
Is Quviviq or Belsomra better?
Neither is universally "better." Quviviq (daridorexant) and Belsomra (suvorexant) are both used for sleep, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Quviviq and Belsomra?
Quviviq is a Dual Orexin Receptor Antagonist made by Idorsia, while Belsomra is a Orexin Receptor Antagonist made by Merck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Quviviq has the larger estimated TV advertising budget of the two.